J Cancer 2022; 13(3):998-1004. doi:10.7150/jca.65835 This issue Cite

Research Paper

Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma

Shi Qiu1,2#, Yizhen Liu2#, Ailing Gui1#, Zuguang Xia2, Wen Liu1, Juan J. Gu3, Ji Zuo1, Ling Yang1✉, Qunling Zhang2✉

1. Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China
2. Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3. Departments of Medicine, Roswell Park Cancer Institute; Buffalo, NY, USA
#These authors contributed equally to this work

Citation:
Qiu S, Liu Y, Gui A, Xia Z, Liu W, Gu JJ, Zuo J, Yang L, Zhang Q. Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma. J Cancer 2022; 13(3):998-1004. doi:10.7150/jca.65835. https://www.jcancer.org/v13p0998.htm
Other styles

File import instruction

Abstract

Graphic abstract

OTUD7B is a deubiquitinase and has been reported as a prognostic factor in various solid tumors. However, its prognostic value in lymphoma patients remains unclear. We detected OTUD7B expression levels in 160 diffuse large B-cell lymphoma (DLBCL) tissue samples by immunohistochemistry, and analyzed correlations between its expression and clinic-pathologic parameters as well as clinical outcomes. We also investigated association between OTUD7B expression and chemotherapeutic drugs anti-tumor activity in vitro. We found that OTUD7B overexpressed in 129 (80.6%) cases, and patients with overexpression of OTUD7B experienced better overall survival comparing to those with OTUD7B low expression (P=0.021). Multivariate Cox regression analysis illustrated that OTUD7B was an independent prognostic indicator. In DLBCL cell lines, we found that Chidamide could up-regulate OTUD7B in several DLBCL cell lines, and also had synergistic effect with doxorubicin at low concentration. Our data illustrated that OTUD7B deficiency is a negative predictor of clinical outcome, and might be a potential therapeutic target in the treatment of diffuse large B-cell lymphoma.

Keywords: OTUD7B, Diffuse large B-cell lymphoma, Rituximab, Chemotherapy, Prognosis


Citation styles

APA
Qiu, S., Liu, Y., Gui, A., Xia, Z., Liu, W., Gu, J.J., Zuo, J., Yang, L., Zhang, Q. (2022). Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma. Journal of Cancer, 13(3), 998-1004. https://doi.org/10.7150/jca.65835.

ACS
Qiu, S.; Liu, Y.; Gui, A.; Xia, Z.; Liu, W.; Gu, J.J.; Zuo, J.; Yang, L.; Zhang, Q. Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma. J. Cancer 2022, 13 (3), 998-1004. DOI: 10.7150/jca.65835.

NLM
Qiu S, Liu Y, Gui A, Xia Z, Liu W, Gu JJ, Zuo J, Yang L, Zhang Q. Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma. J Cancer 2022; 13(3):998-1004. doi:10.7150/jca.65835. https://www.jcancer.org/v13p0998.htm

CSE
Qiu S, Liu Y, Gui A, Xia Z, Liu W, Gu JJ, Zuo J, Yang L, Zhang Q. 2022. Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma. J Cancer. 13(3):998-1004.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.